IP Library Granted Patent US 11,331,325
Granted Patent B2
US 11,331,325 · App. 16/656,178 · Granted May 17, 2022

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Inventors: Robert E. Dudley (Murfreesboro, TN); Panayiotis P. Constantinides (Gurnee, IL)
Assignee: Clarus Therapeutics, Inc.
A61K31/568A61K9/0053A61K9/06A61K9/4858A61K31/22A61K31/573A61K47/10A61K47/12A61K47/14A61K47/26A61K47/44C07J1/00A61K9/1075
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,325
App. No.
16/656,178
Granted
May 17, 2022
Kind
B2
Abstract

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

Claims (9)

1. A method of treating a hypogonadal human male with testosterone deficiency comprising

orally administering to a human male in need thereof an oral pharmaceutical composition comprising 15-20 percent by weight of solubilized testosterone undecanoate, 5-20 percent by weight of hydrophilic surfactant,

wherein the formulation consists of a liquid or semi-solid encased in a capsule, wherein said administration is twice daily, and

wherein the administration provides an average serum concentration of testosterone at steady state of about 300 ng/dl to about 1100 ng/dl.

2. The method as recited in claim 1 , wherein said the hydrophilic surfactant exhibits an HLB of 10 to 45.

3. The method of claim 2 , in which the hydrophilic surfactant is chosen from polyoxyethylene sorbitan fatty acid esters, hydrogenated castor oil ethoxylates, PEG mono- and di-esters of palmitic and stearic acids, fatty acid ethoxylates, and combinations thereof.

4. The method of claim 3 , in which the hydrophilic surfactant is a hydrogenated castor oil ethoxylate.

5. The method of claim 1 , wherein the formulation is a liquid encased in a capsule.

6. The method of claim 1 , wherein the formulation is a semi-solid encased in a capsule.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2022
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 062000/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2020
From: DUDLEY, ROBERT E.; CONSTANTINIDES, PANAYIOTIS P.
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 054641/0925 →
SECURITY INTEREST Recorded Mar 12, 2020
From: CLARUS THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 052099/0349 →
Continuity (7)
Continuation 15723976 · Oct 3, 2017
Continuation 14303179 · Jun 12, 2014
Continuation 13553586 · Jul 19, 2012
Continuation 11911446
Provisional Application 60721971 · Sep 30, 2005
Provisional Application 60671454 · Apr 15, 2005
Related Publication 20200046733A1 · Feb 13, 2020
Cited By (4)
US 12,295,961 US 12,357,643 US 12,403,146 US 12,605,391